Global Primary Sclerosing Cholangitis Treatment Market 2018-2022 | Development of Affordable PSC Drugs to Boost Demand | Technavio
LONDON--(BUSINESS WIRE)--Sep 5, 2018--The global primary sclerosing cholangitis (PSC) treatment market 2018-2022 is expected to post a CAGR of close to 4% during the forecast period, according to the latest market research report by .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180905005961/en/
Technavio has published a new market research report on the global primary sclerosing cholangitis treatment market from 2018-2022. (Graphic: Business Wire)
A key factor driving the growth of the market is the increasing incidence of diseases associated with PSC. Several diseases, such as gallbladder cancer and inflammatory bowel diseases, are associated with primary sclerosing cholangitis. This, in turn, increases the demand for drugs to treat PSC and avoid other liver diseases.
This market research report on the also provides an analysis of the most important trends expected to impact the market outlook during the forecast period. Technavio classifies an emerging trend as a major factor that has the potential to significantly impact the market and contribute to its growth or decline.
In this report, Technavio highlights the development of affordable PSC drugs as one of the key emerging trends in the global primary sclerosing cholangitis treatment market:
Global primary sclerosing cholangitis treatment market: Development of affordable PSC drugs
The available option for the treatment of primary sclerosing cholangitis is liver transplantation. The cost of liver transplantation is high compared with UDCA, which is the only therapeutic present in the market. Several companies are conducting trials of drugs to come up with new therapeutic candidates for the treatment of the disease.
“Some pipeline drugs under study are showing positive results. For instance, the AESOP trial is being conducted to test obeticholic acid for the treatment of primary sclerosing cholangitis. The trial is being conducted by Intercept Pharmaceuticals. PSC drugs are more efficient and affordable as compared to liver transplantation, which is encouraging the companies to develop PSC drugs,” says a senior analyst at Technavio for research on infectious and rare diseases.
Global primary sclerosing cholangitis treatment market: Segmentation analysis
This market research report segments the global primary sclerosing cholangitis treatment market by product (UDCA and others) and geographical regions (APAC, EMEA, and the Americas).
The Americas led the market in 2017 with a market share of more than 52%, followed by APAC and EMEA respectively. The region is expected to continue to dominate during the forecast period.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Market LandscapeMarket ecosystem Market characteristics Market segmentation analysis
Market SizingMarket definition Market size and forecast
Five Forces Analysis
Geographical SegmentationRegional comparison Key leading countries
Vendor LandscapeVendors covered Vendor classification Market positioning of vendors Competitive scenario
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180905005961/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: SURGERY HEALTH ONCOLOGY PHARMACEUTICAL GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 09/05/2018 04:25 PM/DISC: 09/05/2018 04:25 PM